Accreditation/Credit Designation
Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Acknowledgment of Support
This activity is supported by an educational grant from Amgen, Inc.
Oncology Briefings™: Analyzing the Evidence of Biosimilars in HER2-Positive and Supportive Breast Cancer Care Settings
Release Date: August 31, 2021
Expiration Date: August 31, 2022
Activity Overview
This online activity is designed to provide a concise and focused overview on an important clinical topic and includes clinical data supporting the use of approved anti-HER2 monoclonal antibody biosimilars currently available for breast cancer treatment as well as biosimilars of granulocyte colony-stimulating factors (G-CSFs) used in the supportive care setting. The engaging, multimedia format of this program includes audio commentary from an expert thought leader integrated with text-based elements.
Acknowledgement of Commercial Support
This activity is supported by an educational grant from Amgen, Inc.
Instructions for This Activity and Receiving Credit
You may immediately download your certificate. |
Target Audience
This activity is directed toward oncology health care professionals who treat patients with breast cancer, including medical oncologists and radiation oncologists with a particular interest in biosimilars. Fellows, nurses, nurse practitioners, physician assistants, and other health care professionals (HCPs) involved in the management of patients with breast cancer will also be invited to participate.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Understand the differences between biosimilars, generics, reference products, and interchangeable agents for early- and late-stage breast cancer
- Describe the requirements around preclinical data, clinical trials, and post-approval requirements for the regulatory approval of biosimilars
- Highlight efficacy and safety findings from clinical trials that have evaluated biosimilars for use among patients with breast cancer
- Determine multidisciplinary best practices for the practical integration of biosimilars into cancer care plans for patients with breast cancer
Faculty, Staff, and Planners’ Disclosures
The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible entities.
Faculty
Professor of Medicine
Director, Breast Oncology and Clinical Trials Education
University of California, San Francisco
Helen Diller Family Comprehensive Cancer Center
San Francisco, CA
Disclosures: Grant/Research Support: AstraZeneca; Ayala Pharmaceuticals; Boehringer Ingelheim; Daiichi-Sankyo, Inc.; Eli Lilly & Co.; Gilead Sciences, Inc.; MacroGenics; Merck & Co., Inc.; Novartis; Pfizer Inc.; Polyphor; Roche; Seagen Inc.; Sermonix Pharmaceuticals.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
Login or Register to Start Activity
Please use the form below to Register or Log In to begin Activity.
